BioCryst Launches ORLADEYO® (berotralstat) in Ireland [Yahoo! Finance]
BioCryst Launches ORLADEYO® (berotralstat) in Ireland
BioCryst to Present at Upcoming Investor Conferences
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $10.00 price target on the stock.
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $14.00 price target on the stock.